Skip to main content

Table 2 Fungal abundance and phenotypic characteristics of PDACa

From: Oral mycobiota and pancreatic ductal adenocarcinoma

Variables

Mycobiota

Mean ± SDb

Mean ± SDb

P-values

Effect size (95% CI)d

Yes c

No c

Jaundice

g__unclassified_p__Ascomycota

52.0 ± 31.9

30.0 ± `25.7

0.037

22.0 (4.41 ~ 41.7)

Dark brown urine

g__unclassified_p__Ascomycota

51.1 ± 31.1

29.5 ± 26.2

0.037

21.6 (2.08 ~ 38.6)

AJCC staginge

 

Stage I-IIB

Stage III-IV

  

g__unclassified_k__Fungi

47.0 ± 34.8

43.6 ± 29.3

0.759

3.45 (−19. ~ 26.0)

g__unclassified_p__Ascomycota

33.4 ± 29.3

46.8 ± 30.6

0.203

−13.0 (−34. ~ 7.58)

g__Malassezia

0.77 ± 1.87

0.69 ± 2.10

0.907

0.08 (−1.3 ~ 1.47)

Types of Surgeryf

 

Resectable PDAC

Unresectable PDAC

  

g__unclassified_k__Fungi

51.1 ± 32.8

39.7 ± 30.8

0.256

11.3 (−9.6 ~ 32.6)

g__unclassified_p__Ascomycota

34.0 ± 27.1

45.4 ± 32.9

0.228

−11.37 (29.81 ~ 7.60)

g__Malassezia

0.81 ± 1.92

0.65 ± 2.04

0.705

0.15 (−1.1 ~ 1.52)

  1. a PDAC Pancreatic ductal adenocarcinoma patients (n = 34)
  2. b SD Standard deviation
  3. c Yes Patients with a given symptom; No: patients without a given symptoms
  4. d CI Confidence interval
  5. e Patients diagnosed with stage I-IIB (n = 16); patients diagnosed with stage III-IV (n = 18)
  6. f Patients had resectable PDAC (Pancreaticoduodenectomy or Distal pancreatectomy) (n = 17); Patients had unresectable PDAC (Palliative intervention techniques) (n = 17)